Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study With Safety run-in of PD-1 Inhibitor and IgG4 SIRPα-Fc Fusion Protein (TTI-622) in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)

NCT05507541 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT05507541
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05507541 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study With Safety run-in of PD-1 Inhibitor and IgG4 SIRPα-Fc Fusion Protein (TTI-622) in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 19, 2023
Completion date
July 30, 2027
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent alk positive large b-cell lymphoma, recurrent b-cell non-hodgkin lymphoma, recurrent diffuse large b-cell lymphoma associated with chronic inflammation, recurrent diffuse large b-cell lymphoma, not otherwise specified, recurrent ebv-positive diffuse large b-cell lymphoma, not otherwise specified, recurrent grade 3b follicular lymphoma, recurrent gray zone lymphoma, recurrent high grade b-cell lymphoma, recurrent high grade b-cell lymphoma with myc and bcl2 or bcl6 rearrangements, recurrent high grade b-cell lymphoma with myc, bcl2, and bcl6 rearrangements, recurrent high grade b-cell lymphoma, not otherwise specified, recurrent intravascular large b-cell lymphoma, recurrent primary cutaneous diffuse large b-cell lymphoma, leg type, recurrent primary mediastinal (thymic) large b-cell lymphoma, recurrent t-cell/histiocyte-rich large b-cell lymphoma, refractory alk positive large b-cell lymphoma, refractory diffuse large b-cell lymphoma associated with chronic inflammation, refractory diffuse large b-cell lymphoma, not otherwise specified, refractory ebv-positive diffuse large b-cell lymphoma, not otherwise specified, refractory grade 3b follicular lymphoma, refractory high grade b-cell lymphoma, refractory high grade b-cell lymphoma with myc and bcl2 or bcl6 rearrangements, refractory high grade b-cell lymphoma with myc, bcl2, and bcl6 rearrangements, refractory high grade b-cell lymphoma, not otherwise specified, refractory intravascular large b-cell lymphoma, refractory primary cutaneous diffuse large b-cell lymphoma, leg type, refractory primary mediastinal large b-cell lymphoma, refractory t-cell/histiocyte-rich large b-cell lymphoma